14-3-3σ Expression and prognostic value in patients with epithelial ovarian carcinoma: A high throughput tissue microarray analysis
14-3-3σ Expression and prognostic value in patients with epithelial ovarian carcinoma: A high throughput tissue microarray analysis
复制标题
DOI：
10.1016/j.ejso.2008.10.014
复制
发表时间：
2009-07-01
期刊：
影响因子：
3.8
通讯作者：
Odunsi, K.
中科院分区：
文献类型：
--
作者：
Mhawech-Fauceglia, P.;Herrmann, F. R.;Odunsi, K.
目的：14-3-3 sigma 是一种潜在的肿瘤抑制基因，当它被 CpG 甲基化沉默时，可促进癌症的发展。之前，我们通过免疫组织化学证明了人卵巢癌和卵巢癌细胞系中14-3-3 sigma的高甲基化，并且14-3-3 sigma高甲基化与其表达缺失相关。在本研究中，我们的目的是确定 14-3-3 sigma 在预测一系列上皮性卵巢癌患者的疾病结果中的价值。材料和方法：对 192 名具有非常详细特征和中空特征的患者进行肿瘤微阵列 (TMA)。使用 14-3-3 sigma 抗体对载玻片进行免疫染色，其表达与年龄、肿瘤类型、分级、分期、残余肿瘤体积、治疗反应、总生存期 (OS) 和无病生存期 (DFS) 相关。结果：与手术后残余肿瘤体积存在边际关联（χ2 p = 0.044，Fischer 精确值 0.051）。 14-3-3 σ 表达缺失与年龄、分期、分级、肿瘤亚型和临床治疗反应之间没有关联。根据Kaplan-Meier法进行的生存分析显示，14-3-3 sigma表达缺失与OS或DFS无关（分别为p=0.702、p=0.118）。结论：尽管14-3-3 sigma参与卵巢肿瘤发生，但作为预测患者预后的生物标志物不具有预后价值。 (C) 2008 Elsevier Ltd. 保留所有权利。
Aims: 14-3-3 sigma is a potential tumor suppressor gene that when it is silenced by CpG methylation can contribute to cancer development. Previously, we showed that hypermethylation of 14-3-3 sigma in human ovarian cancer and ovarian cancer cell lines, and that 14-3-3 sigma hypermethylation correlated with loss of its expression by immunohistochemistry. In the present study, our aim is to determine the value of 14-3-3 sigma in predicting disease outcome in series of patients with epithelial ovarian cancer.Materials and methods: A tumor microarray (TMA) of 192 patients with a very detailed characteristic and hollow-up was performed. The slides were immunostained with 14-3-3 sigma antibody and its expression was correlated with age, tumor types, grade, stage, volume of residual tumor, response to therapy, overall survival (OS) and disease-free survival (DFS).Results: A marginal association with the volume of residual tumor after surgery (chi2 p = 0.044, Fischer's exact 0.051) was seen. There was no association between loss of 14-3-3 sigma expression and any of age, stage, grade, tumor subtypes, and clinical response to therapy. Survival analysis according to Kaplan-Meier method showed that loss of 14-3-3 sigma expression was not associated with OS or DFS (p=0.702, p = 0.118, respectively).Conclusion: Even though 14-3-3 sigma is involved in ovarian tumorigenesis, it does not have a prognostic value as a biomarker to predict patients' outcome. (C) 2008 Elsevier Ltd. All rights reserved.